FDA Grants Accelerated Approval to Lilly Cancer Drug

News
Article

FDA granted accelerated approval to Eli Lilly and Company’s pirtobrutinib for treatment of relapsed or refractory mantle cell lymphoma.

FDA announced on Jan. 27, 2023, that it has granted accelerated approval to Eli Lilly and Company for Jaypirca (pirtobrutinib) as a treatment for relapsed or refractory mantle cell lymphoma (MCL). Patients who have had at least two lines of systemic therapy, including a bruton tyrosine kinase (BTK) inhibitor, are eligible for the treatment.

Efficacy for pirtobrutinib was evaluated in an open-label, multicenter, single-arm trial (BRUIN [NCT03740529]) of pirtobrutinib monotherapy that included 120 patients with MCL previously treated with a BTK inhibitor. Pirtobrutinib was administered orally at 200 mg once daily and was continued until disease progression or unacceptable toxicity. The main efficacy measures were overall response rate (ORR) and duration of response (DOR). In the results, ORR was measured to be 50%, median DOR was 8.3 months, and the estimated DOR rate at six months was 65.3%.

According to the agency press release, the recommended pirtobrutinib dosage is 200 mg orally once daily until disease progression or unacceptable toxicity. Prior to this accelerated approval, pirtobrutinib received priority review, fast track, and orphan drug designations.

Source: FDA

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes